Abacus Health Products Announces New Retail Purchase Orders and Provides CBDMEDIC™ Update Woonsocket, RI – July 11, 2019 – Abacus Health Products (“Abacus” or the “Company”) (CSE: ABCS) today announced new retail purchase orders for its line of CBDMEDIC™ products, which are sold to consumers via retail chains and the company’s e-commerce platform. Abacus is […]
Abacus Health Products Begins Trading on the OTC Market Woonsocket, RI – July 2, 2019 – Abacus Health Products, Inc. (“Abacus” or the “Company”) (CSE: ABCS) (OTCQX: ABAHF) today announced its subordinate voting shares have begun trading on the OTCQX Market under the symbol “ABAHF” effective July 1, 2019. “Having a dual listing […]
Abacus CEO Perry Antelman to Speak at the Inaugural Institutional Capital & Cannabis Conference Europe Woonsocket, RI – June 13, 2019 – Abacus Health Products (“Abacus” or the “Company”) (CSE: ABCS) CEO Perry Antelman will be a panel participant at the inaugural Institutional Capital & Cannabis Conference Europe (IC3 Europe) to be held in […]
Abacus Health Products Reports First Quarter 2019 Financial Results Toronto, ON – May 30, 2019 – Abacus Health Products, Inc. (CSE: ABCS) (“Abacus” or the “Company”) reported its financial results today for the first quarter ended March 31, 2019. All amounts are in U.S. dollars unless indicated otherwise. Q1 2019 Financial Summary Revenue increased 166% […]
Abacus Health Products, Inc. (CSE: ABCS) announced that renowned Hollywood fitness trainer and nutritional expert, Harley Pasternak, will be working with the Company to increase public awareness of its CBDMEDIC™ line of pain relief and skincare products.
Abacus Health Products, Inc. (CSE: ABCS) will release its 2019 first quarter financial results on Thursday, May 30, 2019, after market close. Management will host a conference call the following day, Friday, May 31, 2019, at 10:00 AM Eastern Time to review the financial results.
Abacus Health Products, Inc. (CSE: ABCS) announced the closing of its bought deal offering of 2,464,450 units including the exercise, in full, of the Underwriters’ over-allotment option for gross proceeds of $34,502,300.
Abacus Health Products, Inc. (CSE: ABCS) released the financial results of its operating subsidiary, Abacus Health Products, Inc., a Delaware corporation, for the 12-month period ending December 31, 2018, being a period completed prior to the closing of the Company’s reverse takeover transaction with Abacus U.S. completed on January 29, 2019 .
James Barkat has been named Vice President of Marketing for Abacus. Prior to joining the Company, Mr. Barkat spent over ten years at Sanofi Consumer Health, where he most recently served as U.S.